Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
BMC Health Services Research
|
January 15, 2023
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy
Roberto Cairoli, Gianluca Furneri, Roberto Di Virgilio, et al.
The Journal of Mental Health Policy and Economics
|
April 23, 2002
Depression: cost-of-illness studies in the international literature, a review
Patrizia Berto, Daniele D'Ilario, Pierfrancesco Ruffo, et al.
Global & Regional Health Technology Assessment
|
July 18, 2025
Carolina Moreno, Andrea Aiello, Roberto Di Virgilio, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
March 28, 2024
Acute treatment of migraine: quantifying the unmet need through real-world data in Italy
Simona Sacco, Sonia Di Ciaccio, Roberto Di Virgilio, et al.
Vaccines
|
December 23, 2022
Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
Barbara Polistena, Giancarlo Icardi, Andrea Orsi, et al.
Infectious Diseases and Therapy
|
July 18, 2025
Complementary Strategy of Maternal Immunization with RSVpreF Vaccine and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment
Barbara Polistena, Fabio Midulla, Giovanni Sotgiu, et al.
Clinical Therapeutics
|
May 1, 2020
Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy
Eszter Tichy, Antoni Torres, Matteo Bassetti, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
April 15, 2026
Cost-Effectiveness of Bivalent Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Among Older Adults in Italy
Sergio Di Matteo, Paolo Bonanni, Sara Boccalini, et al.
Antimicrobial Resistance and Infection Control
|
January 1, 2020
Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)
Thitima Kongnakorn, Christian Eckmann, Matteo Bassetti, et al.
International Journal of Antimicrobial Agents
|
June 17, 2019
Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections
Thitima Kongnakorn, Florian Wagenlehner, Marco Falcone, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
BMC Health Services Research
|
January 15, 2023
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy
Roberto Cairoli, Gianluca Furneri, Roberto Di Virgilio, et al.
The Journal of Mental Health Policy and Economics
|
April 23, 2002
Depression: cost-of-illness studies in the international literature, a review
Patrizia Berto, Daniele D'Ilario, Pierfrancesco Ruffo, et al.
Global & Regional Health Technology Assessment
|
July 18, 2025
Carolina Moreno, Andrea Aiello, Roberto Di Virgilio, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
March 28, 2024
Acute treatment of migraine: quantifying the unmet need through real-world data in Italy
Simona Sacco, Sonia Di Ciaccio, Roberto Di Virgilio, et al.
Vaccines
|
December 23, 2022
Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
Barbara Polistena, Giancarlo Icardi, Andrea Orsi, et al.
Infectious Diseases and Therapy
|
July 18, 2025
Complementary Strategy of Maternal Immunization with RSVpreF Vaccine and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment
Barbara Polistena, Fabio Midulla, Giovanni Sotgiu, et al.
Clinical Therapeutics
|
May 1, 2020
Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy
Eszter Tichy, Antoni Torres, Matteo Bassetti, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
April 15, 2026
Cost-Effectiveness of Bivalent Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Among Older Adults in Italy
Sergio Di Matteo, Paolo Bonanni, Sara Boccalini, et al.
Antimicrobial Resistance and Infection Control
|
January 1, 2020
Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)
Thitima Kongnakorn, Christian Eckmann, Matteo Bassetti, et al.
International Journal of Antimicrobial Agents
|
June 17, 2019
Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections
Thitima Kongnakorn, Florian Wagenlehner, Marco Falcone, et al.
Page
of 3